scholarly journals Improvement In Colorectal Cancer Outcomes Over Time is Limited To Patients With Left-Sided Disease

Author(s):  
Holger Rumpold ◽  
Monika Hackl ◽  
Andreas Petzer ◽  
Dominik Wolf

Abstract Purpose: Incidence and mortality of colorectal cancer (CRC) declined over the last decades. However, survival depends on the primary tumor location. It is unknown if all progress in outcomes vary depending on left-sided (LCRC) versus right sided (RCC) colorectal cancer. We compare incidence and mortality rates over time according to the primary tumor location. Methods: Data from the Austrian National Cancer Registry spanning from 1983 to 2018 were used to calculate annual incidence and mortality rates and survival stratified by primary tumor localization and stage. Joinpoint regression with linear regression models were used on different subgroups to identify significant changes of incidence- and mortality slopes.Results: A total of 168,260 (incidence-data set) and 87,355 cases (mortality data-set) were identified. Survival of disseminated RCC was worse compared to LCRC (HR 1.14; CI 1.106 – 1.169). Total and LCRC incidence- and mortality-rates declined steadily over time, whereas the rates of RCC did not. Incidence of disseminated RCC declined significantly less (slope -0.07; CI -0.086; -0.055) than in LCRC (slope -0.159; CI -0.183; -0.136); mortality rate of RCC was unchanged over time. Incidence and mortality of localized RCC remained unchanged over time, whereas both rates declined independently of stage in LCRC. Conclusion: Colorectal cancer outcomes during the last 35 years have preferentially improved in LCRC but not in RCC, indicating that the progress made is limited to LCRC. It is necessary to define RCC as a distinct form of CRC and to focus on specific strategies for its early detection and treatment.

2012 ◽  
Vol 102 (9) ◽  
pp. 1791-1797 ◽  
Author(s):  
Amanda I. Phipps ◽  
John Scoggins ◽  
Mary Anne Rossing ◽  
Christopher I. Li ◽  
Polly A. Newcomb

2021 ◽  
Author(s):  
George Kafatos ◽  
Victoria Banks ◽  
Peter Burdon ◽  
David Neasham ◽  
Kimberly A Lowe ◽  
...  

Background: Advances in therapies for patients with metastatic colorectal cancer (mCRC) and improved understanding of prognostic and predictive factors have impacted treatment decisions. Materials & methods: This study used a large oncology database to investigate patterns of monoclonal antibody (mAb) plus chemotherapy treatment in France, Germany, Italy, Spain and the UK in mCRC patients treated in first line in 2018. Results: Anti-EGFR mAbs were most often administered to patients with RAS wild-type mCRC and those with left-sided tumors, while anti-VEGF mAbs were preferred in RAS mutant and right-sided tumors. Adopted treatment strategies differed between countries, largely due to reimbursement. Conclusion: Biomarker status and primary tumor location steered treatment decisions in first line. Adopted treatment strategies differed between participating countries.


2018 ◽  
Vol 15 (14) ◽  
pp. 1640-1647
Author(s):  
Xiaona Cai ◽  
Dianna Gu ◽  
Mengfeng Chen ◽  
Linger Liu ◽  
Didi Chen ◽  
...  

2020 ◽  
Vol 9 (14) ◽  
pp. 5221-5234
Author(s):  
Matilda Holm ◽  
Sakari Joenväärä ◽  
Mayank Saraswat ◽  
Tiialotta Tohmola ◽  
Ari Ristimäki ◽  
...  

2017 ◽  
Vol 28 ◽  
pp. iii118-iii119
Author(s):  
Gonçalo Atalaia ◽  
Marta Vaz Baptista ◽  
Tiago Tomás ◽  
Susana Almeida ◽  
Inês Eiriz ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document